Last reviewed · How we verify
NCT06748703
Optic Nerve Injury in Obstructive Sleep Apnea Patients
NA trial testing CPAP Treatment in Obstructive Sleep Apnea (OSA) in 80 participants. Currently enrolling.
31 December 2025
Quick facts
| Lead sponsor | Nanjing Medical University |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 80 |
| Start date | 1 January 2025 |
| Primary completion | 31 December 2025 |
| Estimated completion | 31 January 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- CPAP Treatment
Conditions studied
- Obstructive Sleep Apnea (OSA) — all drugs for Obstructive Sleep Apnea (OSA) →
- Ischemic Optic Neuropathy/Optic Nerve Stroke — all drugs for Ischemic Optic Neuropathy/Optic Nerve Stroke →
Sponsor
Nanjing Medical University
Who can join
Adults 18 to 80, any sex, with Obstructive Sleep Apnea (OSA) or Ischemic Optic Neuropathy/Optic Nerve Stroke. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Ischemic optic neuropathy (ION) is damage to the optic nerve caused by ischemia and hypoxia of the optic nerve due to an impairment of the blood supply to the optic nerve from the arteries. Obstructive Sleep Apnea Hypoventilation Syndrome (OSAHS) is a sleep-breathing disorder characterized by recurrent upper airway obstruction and apnea during sleep, leading to recurrent intermittent hypoxemia with fragmented sleep and daytime sleepiness. Due to the lack of accurate methods to evaluate blood flow, the correlation between the two is unclear and uncertain. The study will enroll 80 patients from the First Affiliated Hospital of Nanjing Medical University and categorize them into mild, moderate, and severe OSA groups according to their apnea-hypopnea index (AHI). Participants will undergo a baseline evaluation, including polysomnography (PSG) and ophthalmologic examinations such as optic nerve and macular blood flow OCT, visual acuity, refraction, intraocular pressure, and visual fields. Eligible patients will be treated with CPAP for 3 months, after which their PSG and ophthalmologic examination-related results will be re-evaluated to assess treatment efficacy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06748703
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of CPAP Treatment
Trials testing the same drug.
- NCT06554496 — XOR Levels in OSA Patients (XOR-OSA) · NA · recruiting
- NCT04407949 — Comparison of Sleep Disordered Breathing Events Detected by the CPAP Device "prismaLine" With Polysomnography · NA · completed
Other recruiting trials for Obstructive Sleep Apnea (OSA)
Currently open trials in the same condition.
- NCT07292922 — Digital-supported Orofacial Myofunctional Therapy in OSA · NA · recruiting
- NCT06983769 — CPAP vs MAD for OSA in Patients With Cognitive Impairment. A Randomized Clinical Trial · NA · recruiting
- NCT07307560 — High-Flow Nasal Cannula for Preventing Hypoxia During Sedated Endoscopy in High-Risk Obstructive Sleep Apnea Patients · NA · recruiting
- NCT07103941 — IOA Preventing Occlusal Changes With MAD Use · NA · recruiting
- NCT07121452 — Telehealth for Sleep Apnea: Effectiveness, Implementation, and Cost in the Military Health System · NA · recruiting
Other Nanjing Medical University trials
Trials by the same sponsor.
- NCT07382375 — AI-assisted Subtyping-directed Precision Treatment in Acute Aortic Dissection · NA · not yet recruiting
- NCT07494474 — Risk Assessment of Pancreatic Islet Autoimmunity in Patients With AITD · not yet recruiting
- NCT07482774 — Tumor Microenvironment Changes After Neoadjuvant Chemo-Immunotherapy in Esophageal Squamous Cell Carcinoma · not yet recruiting
- NCT07348328 — Vitamin B Supplementation for Patients Undergoing Cardiovascular Surgery · NA · not yet recruiting
- NCT07258394 — Clinical Study for Dimethyl Fumarate in Preserving Islet β-Cell Function in Type 1 Diabetes Mellitus · Phase 3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06748703 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Nanjing Medical University
- Last refreshed: 27 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06748703.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing